Genmab A/S
GNMSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $97 | $139 | $194 | $167 |
| - Cash | $10 | $15 | $10 | $9 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $88 | $125 | $185 | $158 |
| Revenue | $22 | $16 | $15 | $8 |
| % Growth | 30.7% | 12.9% | 72.1% | – |
| Gross Profit | $21 | $16 | $15 | $8 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| EBITDA | $10 | $6 | $7 | $4 |
| % Margin | 45% | 36.4% | 50.2% | 49.3% |
| Net Income | $8 | $4 | $5 | $3 |
| % Margin | 36.4% | 26.4% | 37.4% | 34.9% |
| EPS Diluted | 121.36 | 66.02 | 82.59 | 45.54 |
| % Growth | 83.8% | -20.1% | 81.4% | – |
| Operating Cash Flow | $8 | $7 | $4 | $2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $8 | $7 | $4 | $2 |